Business Wire

06 Jun 2026, 18:45 UTC · 3h ago

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Read original · https://www.businesswire.com/news/home/20260606323066/en/Dexcom-CONNECT-Study-The-Most-Significant-Clinical-Study-Demonstrating-CGM-Benefits-for-People-with-Type-2-Diabetes-Not-Using-Insulin/

Top 1 mover · tap to explore

Story key points

1 claims · impact-rated

What matters in this story

1
The CONNECT trial showed Dexcom G7 leads to statistically significant A1C reduction and improved glucose control in non-insulin-using Type 2 diabetes patients. — Positive clinical data for a larger patient population (non-insulin T2D) expands the addressable market and potential for broader insurance reimbursement.
+0.60

Ticker attribution

Model heads

Sentiment in this article

DXCM+0.80
Positive clinical trial results show the Dexcom G7 significantly improves glucose control in Type 2 diabetes patients.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

DXCM

Browse live screenings

Impact vectors

6 related stories

Reuters
3h ago
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
- diabetes
- glucose monitoring
- healthcare
Read

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrati… · News Impact Screener

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i